United States:
PTAB Institutes IPR Proceedings Against Mayne Pharma's Antifungal Formulation Patent, PTAB Litigation Blog
11 January 2017
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
The PTAB instituted an IPR on claims of Mayne Pharma
International Pty Ltd.'s ("Mayne") U.S. Patent No.
6,881,745 B2 covering formulations of azole antifungals in IPR2016-01186. In response to Merck
Sharp & Dohme Corp.'s ("Merck") Petition, the
PTAB instituted review of some claims on anticipation grounds, and
of all challenged claims on the grounds of obviousness.
Read the full article at
ptablitigationblog.com.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.